Share-based Payment Arrangement, Expense of Compass Therapeutics, Inc. from 30 Jun 2019 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Compass Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2019 to 30 Sep 2025.
  • Compass Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,238,000, a 44% decline year-over-year.
  • Compass Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $8,781,000, a 11% increase year-over-year.
  • Compass Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $8,560,000, a 40% increase from 2023.
  • Compass Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $6,120,000, a 15% increase from 2022.
  • Compass Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $5,330,000, a 32% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Compass Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $8,781,000 $1,238,000 -$960,000 -44% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $9,741,000 $2,791,000 +$670,000 +32% 01 Apr 2025 30 Jun 2025 10-Q 11 Aug 2025 2025 Q2
Q1 2025 $9,071,000 $2,514,000 +$511,000 +26% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $8,560,000 $2,238,000 +$638,000 +40% 01 Oct 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
Q3 2024 $7,922,000 $2,198,000 +$573,000 +35% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025 2025 Q3
Q2 2024 $7,349,000 $2,121,000 +$493,000 +30% 01 Apr 2024 30 Jun 2024 10-Q 11 Aug 2025 2025 Q2
Q1 2024 $6,856,000 $2,003,000 +$736,000 +58% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $6,120,000 $1,600,000 +$575,000 +56% 01 Oct 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
Q3 2023 $5,545,000 $1,625,000 +$338,000 +26% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $5,207,000 $1,628,000 +$184,000 +13% 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024 2024 Q2
Q1 2023 $5,023,000 $1,267,000 -$307,000 -20% 01 Jan 2023 31 Mar 2023 10-Q 13 May 2024 2024 Q1
Q4 2022 $5,330,000 $1,025,000 -$121,000 -11% 01 Oct 2022 31 Dec 2022 10-K 21 Mar 2024 2023 FY
Q3 2022 $5,451,000 $1,287,000 +$300,000 +30% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $5,151,000 $1,444,000 +$496,000 +52% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023 2023 Q2
Q1 2022 $4,655,000 $1,574,000 +$626,000 +66% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q4 2021 $4,029,000 $1,146,000 +$96,000 +9.1% 01 Oct 2021 31 Dec 2021 10-K 15 Mar 2023 2022 FY
Q3 2021 $3,933,000 $987,000 -$1,549,000 -61% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 $5,482,000 $948,000 +$765,000 +418% 01 Apr 2021 30 Jun 2021 10-Q 01 Aug 2022 2022 Q2
Q1 2021 $4,717,000 $948,000 +$701,000 +284% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q4 2020 $4,016,000 $1,050,000 01 Oct 2020 31 Dec 2020 10-K 18 Mar 2022 2021 FY
Q3 2020 $2,536,000 +$2,287,000 +918% 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2020 2020 Q3
Q2 2020 $183,000 -$2,000 -1.1% 01 Apr 2020 30 Jun 2020 10-Q 13 Aug 2020 2020 Q2
Q1 2020 $247,000 01 Jan 2020 31 Mar 2020 10-Q 30 Apr 2021 2021 Q1
Q3 2019 $249,000 01 Jul 2019 30 Sep 2019 10-Q 09 Nov 2020 2020 Q3
Q2 2019 $185,000 01 Apr 2019 30 Jun 2019 10-Q 13 Aug 2020 2020 Q2

Compass Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $8,560,000 +$2,440,000 +40% 01 Jan 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
2023 $6,120,000 +$790,000 +15% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
2022 $5,330,000 +$1,301,000 +32% 01 Jan 2022 31 Dec 2022 10-K 21 Mar 2024 2023 FY
2021 $4,029,000 +$13,000 +0.32% 01 Jan 2021 31 Dec 2021 10-K 15 Mar 2023 2022 FY
2020 $4,016,000 +$3,101,000 +339% 01 Jan 2020 31 Dec 2020 10-K 18 Mar 2022 2021 FY
2019 $915,000 01 Jan 2019 31 Dec 2019 10-K 05 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.